Boston-based Verve Therapeuticss’ study for its one-time drug treatment found patients treated with possible therapeutic doses had between a 39% and 55% reduction in LDL cholesterol.
A second drug, lepodisiran, reduced the harmful risk factor lipoprotein(a) by 94%. The reductions lasted nearly a year, according to the phase 1 study published in the Journal of the American Medical Association. Lp(a) is a form of cholesterol with characteristics in common with LDL cholesterol, according to a Nov. 12 American Heart Association news release.
Leave a Reply